Skip to main content
SpringerLink
Log in

Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objective

Veliparib (ABT-888) is a potent oral inhibitor of Poly(ADP-ribose) polymerase enzyme that is currently in development for the treatment of non-hematologic and hematologic malignancies. This analysis characterizes the population pharmacokinetics of veliparib, including developing a structural pharmacokinetic model and testing patient demographics and covariates for potential influence on veliparib pharmacokinetics in patients with non-hematologic malignancies.

Methods

The analysis dataset included 3,542 veliparib concentration values from 325 patients with non-hematologic malignancies enrolled in three phase I and one phase II studies. Population pharmacokinetic modeling was performed using NONMEM. The likelihood ratio test was used for comparison of nested models, and visual predictive check was employed for model qualification. Covariates tested included body size measures, creatinine clearance (CLCR), formulation, age, sex, race, liver function tests, and coadministration with temozolomide.

Results

A one-compartment model with first-order absorption and elimination adequately described veliparib pharmacokinetics. The final model included fixed effects for CLCR on veliparib oral clearance (CL/F) and lean body mass (LBM) on volume of distribution (V d/F). CL/F and V d/F were 20.9 L/h (for a CLCR of 100 mL/min) and 173 L (for an LBM of 56 kg), respectively.

Conclusion

Only LBM and CLCR were found to be determinants of veliparib V d/F and CL/F, respectively. Dosage adjustments of veliparib on the basis of body size, age, sex, race, liver function, and temozolomide coadministration are not necessary in patients with non-hematologic malignancies. This is the first study to characterize the population pharmacokinetics of veliparib, and the developed model will be used to conduct simulations and evaluate veliparib exposure-response relationships.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chiarugi A. Poly (ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited. Trends Pharmacol Sci. 2002;23(3):122.

    Article  CAS  PubMed  Google Scholar 

  2. Virág L, Szabó C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375–429.

    Article  PubMed  Google Scholar 

  3. Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem/FEBS. 1980;104(1):279.

    Article  CAS  Google Scholar 

  4. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly (ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol. 1991;37(4):223–7.

    Article  CAS  PubMed  Google Scholar 

  5. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2001;16(3):338–44.

    Article  CAS  PubMed  Google Scholar 

  6. Hirai K, Ueda K, Hayaishi O. Aberration of poly (adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983;43(7):3441–6.

    CAS  PubMed  Google Scholar 

  7. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277–90.

    Article  CAS  PubMed  Google Scholar 

  8. Penning TD, Zhu G-D, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2008;52(2):514–23.

    Article  Google Scholar 

  9. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–37.

    Article  CAS  PubMed  Google Scholar 

  10. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011;71(17):5626–34.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Li X, Delzer J, Voorman R, de Morais SM, Lao Y. Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase. Drug Metab Dispos. 2011;39(7):1161–9.

    Article  CAS  PubMed  Google Scholar 

  14. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010;65(3):419–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57.

    Article  PubMed  Google Scholar 

  16. Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM user’s guide. Ellicott City: Icon Development Solutions; 1989–2009.

  17. Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.

    Article  CAS  PubMed  Google Scholar 

  18. Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000;39(3):215–31.

    Article  CAS  PubMed  Google Scholar 

  19. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43(15):1167–78.

    Article  PubMed  Google Scholar 

  20. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.

    Article  PubMed  Google Scholar 

  21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  PubMed  Google Scholar 

  22. Mosteller R. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.

    CAS  PubMed  Google Scholar 

  23. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558–69.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metabol Pharmacokinet. 2009;24(1):25–36.

    Article  CAS  Google Scholar 

  26. Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115–22.

    Article  CAS  PubMed  Google Scholar 

  27. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67(1):93–101.

    Article  CAS  PubMed  Google Scholar 

  28. Morgan D, Bray K. Lean body mass as a predictor of drug dosage: implications for drug therapy. Clin Pharmacokinet. 1994;26(4):292.

    Article  CAS  PubMed  Google Scholar 

  29. Roche A, Heymsfield S, Lohman T, editors. Human body composition. Champaign (IL): Human Kinetics Press; 1996.

  30. Kikuchi R, Lao Y, Bow DA, Chiou WJ, Andracki ME, Carr RA, et al. Prediction of clinical drug–drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K). J Pharm Sci. 2013;102(12):4426–32.

    Article  CAS  PubMed  Google Scholar 

  31. Mehta MP, Curran WJ, Wang D, Wang F, Kleinberg L, Brade A, et al. Phase 1 safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (PTS) with brain metastases. J Thorac Oncol. 2012;84(3S):S269.

    Google Scholar 

  32. Middleton M, Friedlander P, Hamid O, Daud A, Plummer R, Schuster R, et al. Efficacy of veliparib (ABT-888) plus temozolomide versus temozolomide alone: a randomized, double-blind, placebo-controlled trial in patients with metastatic melanoma. Eur J Cancer. 2011;47:8.

    Article  Google Scholar 

Download references

Acknowledgments

This study was sponsored by AbbVie, who contributed to the study design, research, and interpretation of data, and writing, reviewing, and approving the publication. Ahmed Hamed Salem, Vincent L. Giranda, and Nael M. Mostafa are employees of AbbVie. The authors would like to thank Teresa Turner (AbbVie) for medical writing support.

Author information

Authors and Affiliations

  1. Clinical Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA

    Ahmed Hamed Salem, Vincent L. Giranda & Nael M. Mostafa

  2. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

    Ahmed Hamed Salem

Authors
  1. Ahmed Hamed Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent L. Giranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nael M. Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed Hamed Salem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salem, A.H., Giranda, V.L. & Mostafa, N.M. Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies. Clin Pharmacokinet 53, 479–488 (2014). https://doi.org/10.1007/s40262-013-0130-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-013-0130-1

Keywords

Search

Navigation